[High prevalence of secondary hyperparathyroidism due to vitamin D insufficiency in Graves' disease].
We studied concentrations of serum calcium, intact parathyroid hormone (iPTH), and 25 hydroxyvitamin D (25 [OH] D) in 343 patients with Graves' disease (273 women, 70 men) during one year period. The serum 25 (OH) D levels were 37+/-19 nmol/L and vitamin D deficiency (defined as a serum 25 (OH) D value below 25 nmol/L) was found in 35% of the patients. There was a significant seasonal variation in the 25 (OH) D concentrations, with high values of 51+/-21 nmol/L during the summer term (July-September), and with low values of 26+/-17 nmol/L during the winter term (January-March). The average serum iPTH level was 48+/-26 pg/mL, with 26% (89/343) having values above the normal range. Our results showed high prevalence of secondary hyperparathyroidism in patients with Graves' disease during antithyroid drug therapy and vitamin D and/or calcium supplements are recommended for patients with vitamin D deficiency.
Doi
Yasuko
Y
Noguchi Thyroid Clinic and Foundation.
Yamashita
Hiroyuki
H
Noguchi
Shiro
S
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002112:Calcifediol / Q000097:blood; D005260:Female; D006111:Graves Disease / Q000150:complications* / Q000628:therapy; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D015995:Prevalence; D012621:Seasons; D014808:Vitamin D Deficiency / Q000175:diagnosis / Q000209:etiology*
D013956:Antithyroid Agents; D015415:Biomarkers; D010281:Parathyroid Hormone; D002112:Calcifediol